Sida 1 från 52 resultat
Women patients with breast cancer referring to Shohaday-e- Tajrish Hospital of Tehran who are under chemotherapy treatment. In order to blind the investigator, medications are named as "A" for syrup of HB and B for placebo. The patients don't aware of the type of drug they are assigned to. In
TNBC is an aggressive subtype of breast cancer associated with poor survival and new treatments are needed. A key feature of cancer is its ability to go undetected by the immune system. Recent developments in cancer research have identified immune checkpoints as a possible treatment option as they
Hyperuricemia is considered one of the risk factors for arterial hypertension in postmenopausal women. The recent analysis by Loeffler confirmed that, as indicated in the NHANES survey, uric acid is a powerful cardiovascular risk factor.Analysis of age and sex strata in a meta-analysis showed
The study will follow the Declaration of Helsinki and the Spaniard legislation regarding clinical research. Data obtained will be confidential and only the researchers and participants, upon request, will have access to them. The study will also follow the data protection legislation of Spain to
Pre- and post-menopausal women age ≥ 18 years with unresectable, ER-positive and/or PR-positive and HER2-negative locally-recurrent or metastatic breast cancer (mBC) with no prior line of chemotherapy in the metastatic setting, and that have shown progression while on an aromatase
TNBC is an aggressive subtype of breast cancer associated with poor survival and new treatments are needed. A key feature of cancer is its ability to go undetected by the immune system. Recent developments in cancer research have identified immune checkpoints as a possible treatment option as they
Elderly cancer patients are a special group, often complicated by a variety of chronic diseases, which bring serious obstacles to surgery and adjuvant treatment. It is for these reasons that most patients with high-level evidence-based randomized controlled clinical trials will be part of these
Preoperative preparation:
History taking, physical examination, and investigations will be done according to the local protocol designed to evaluate the patients. This includes complete blood count, blood sugar level, serum urea and creatinine, liver function tests, coagulation profile and
This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab) in comparison to Herceptin® (Genentech/Roche) in patients with Human
OUTLINE: This is a multi-center study.
INVESTIGATIONAL TREATMENT:
- bicalutamide - 150mg po daily D1 - D28 (Cycle = 28 days)
- ribociclib po daily D1 - D21 of 28 day cycle
PHASE I SAFETY RUN-IN COHORT:
The maximum tolerated dose (MTD) of bicalutamide in combination with ribociclib will be determined
The patients will be allocated into two groups: exercise group (intervention) and conventional treatment group (active comparison). Intervention: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive
The FG-3019 treatment will be administered over a 28-day cycle:
- Dose: 35 mg/kg
- Route: IV over one hour following completion of gemcitabine infusion
- Schedule:
- Days 1, 8, and 15
- Please note that Day 8 infusion will on be completed during the first treatment cycle
On Drug Evaluation
The
Purpose of the Study:
The purpose of this prospective study is to determine the diagnostic value of Magnetic Resonance Imaging (MRI) for the evaluation of patients with pathologic nipple discharge.
Background & Significance:
Nipple discharge, one of the most common reasons for referral to the breast
1. Introduction to investigational treatment(s) and other study treatment(s)
1.1 Overview of gemcitabine Gemcitabine (29,29-difluoro 29-deoxycytidine, dFdC) which developed from cytosine arabinoside (Ara-C) is an nucleoside analog used as chemotherapy. It was intended as an antiviral drug in
OUTLINE: This is a multi-center trial.
INVESTIGATIONAL TREATMENT:
- Palbociclib 125 mg will be administered orally once daily on days 1-21 (D1-D21) of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
- Tamoxifen 20 mg will be administered orally once daily for every day of the